Clinical trials with MEK inhibitors for neuroblastoma are ongoing (NCT06104488 and NCT02124772) in single treatment or in combination with CDK4/6 inhibitor ribociclib and BRAF inhibitor dabrafenib [36–39]. Here, MAP2K7 is linked to neuroblastoma.